{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:10:10Z","timestamp":1761235810031},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>Purpose of review<\/jats:title><jats:p>The severity of each organ involvement, natural course, and response to therapies are extremely heterogeneous among patients with systemic sclerosis (SSc). The discovery and validation of biomarkers can help identify disease risk, improve early diagnosis and prognosis, better design clinical trials and assess response to treatment, and further elucidate the underlying pathogenic mechanisms of this disease. The goal of this review is to summarize recent advances into the field of SSc biomarker development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Recent findings<\/jats:title><jats:p>The use of both traditional and next-generation techniques, including large-scale transcriptomic, epigenomic, and proteomic technologies, has yielded a slew of new candidate biomarkers that correlate with different SSc clinical phenotypes. Recent evidence indicates that skin gene expression-based pharmacodynamic biomarkers have the potential to be employed as surrogate measures of clinical endpoints (i.e. modified Rodnan skin thickness score) providing objective assessment of response in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Summary<\/jats:title><jats:p>Several promising biomarkers addressing key unmet needs related to the evaluation and management of SSc patients have been recently proposed. Nevertheless, these biomarkers still require rigorous validation in prospective studies and have yet to make their way into clinical practice and therapeutic development. Robust biomarkers, ideally mechanistic ones, are needed to enable precision medicine in SSc.<\/jats:p><\/jats:sec>","DOI":"10.1097\/bor.0000000000000324","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T11:47:42Z","timestamp":1467632862000},"page":"606-612","source":"Crossref","is-referenced-by-count":11,"title":["Emerging biomarkers in systemic sclerosis"],"prefix":"10.1097","volume":"28","author":[{"given":"Mirko","family":"Manetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230829","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"R2-20230829","doi-asserted-by":"crossref","first-page":"e2696","DOI":"10.1371\/journal.pone.0002696","article-title":"Molecular subsets in the gene expression signatures of scleroderma skin","volume":"3","author":"Milano","year":"2008","journal-title":"PLoS One"},{"key":"R3-20230829","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1002\/art.39289","article-title":"Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis","volume":"67","author":"Assassi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R4-20230829","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20230829","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11926-016-0582-z","article-title":"Clinical trial design issues in systemic sclerosis: an update","volume":"18","author":"Gordon","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"R6-20230829","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00281-015-0506-4","article-title":"Update on biomarkers in systemic sclerosis: tools for diagnosis and treatment","volume":"37","author":"Affandi","year":"2015","journal-title":"Semin Immunopathol"},{"key":"R7-20230829","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.autrev.2014.12.001","article-title":"Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis","volume":"14","author":"Chora","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R8-20230829","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/BOR.0000000000000237","article-title":"Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data","volume":"28","author":"Martyanov","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"R9-20230829","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual, framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20230829","first-page":"1271","article-title":"Variability of skin scores and clinical measurements in scleroderma","volume":"22","author":"Pope","year":"1995","journal-title":"J Rheumatol"},{"key":"R11-20230829","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","article-title":"Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial","volume":"43","author":"Clements","year":"2000","journal-title":"Arthritis Rheum"},{"key":"R12-20230829","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"6","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R13-20230829","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R14-20230829","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1002\/art.39287","article-title":"A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"67","author":"Rice","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R15-20230829","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/art.27220","article-title":"A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis","volume":"62","author":"Farina","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R16-20230829","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"R17-20230829","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"R18-20230829","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/annrheumdis-2012-202843","article-title":"The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis","volume":"73","author":"Abignano","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R19-20230829","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","article-title":"Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R20-20230829","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","author":"Brkic","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R21-20230829","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1515\/cclm-2015-0079","article-title":"Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis","volume":"53","author":"Leg\u00e1ny","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"R22-20230829","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1002\/art.22263","article-title":"Domain 1 of the urokinase-type plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells","volume":"54","author":"Margheri","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R23-20230829","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2013-203706","article-title":"Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?","volume":"73","author":"Manetti","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R24-20230829","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/annrheumdis-2015-207803","article-title":"Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice","volume":"75","author":"Manetti","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R25-20230829","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14699","article-title":"A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis","author":"Takahashi","year":"2016","journal-title":"Br J Dermatol"},{"key":"R26-20230829","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13075-015-0749-4","article-title":"Plexin-D1\/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis","volume":"17","author":"Mazzotta","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R27-20230829","article-title":"Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis","author":"Romano","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"(4 Suppl 91)","key":"R28-20230829","first-page":"S127","article-title":"Predictive value of vascular disease biomarkers for digital ulcers in systemic sclerosis patients","volume":"33","author":"Silva","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R29-20230829","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/rheumatology\/kew017","article-title":"Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients","volume":"55","author":"Cossu","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R30-20230829","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R31-20230829","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3876","article-title":"N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study","volume":"14","author":"Thakkar","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R32-20230829","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R33-20230829","article-title":"The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study","author":"Thakkar","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"R34-20230829","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13075-015-0712-4","article-title":"Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study","volume":"17","author":"McMahan","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"R35-20230829","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.intimp.2015.07.042","article-title":"Critical roles of microRNAs in the pathogenesis of systemic sclerosis: new advances, challenges and potential directions","volume":"28","author":"Miao","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"R36-20230829","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1093\/rheumatology\/kev234","article-title":"Specific autoantibody profiles and disease subgroups correlate with circulating micro-RNA in systemic sclerosis","volume":"54","author":"Wuttge","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"R37-20230829","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"(4 Suppl 91)","key":"R38-20230829","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"R39-20230829","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/art.39558","article-title":"Antiinterferon-inducible protein 16 antibodies associate with digital gangrene in patients with scleroderma","volume":"68","author":"McMahan","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R40-20230829","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11926-015-0505-4","article-title":"Functional autoantibodies in systemic sclerosis pathogenesis","volume":"17","author":"Kill","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"R41-20230829","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R42-20230829","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.150061","article-title":"Autoantibodies against endothelin 1 type a receptor are strong predictors of digital ulcers in systemic sclerosis","volume":"42","author":"Avouac","year":"2015","journal-title":"J Rheumatol"},{"key":"R43-20230829","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"R44-20230829","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R45-20230829","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.39125","article-title":"Epitope specificity determines pathogenicity and detectability of antiplatelet-derived growth factor receptor \u03b1 autoantibodies in systemic sclerosis","volume":"67","author":"Moroncini","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"R46-20230829","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R47-20230829","doi-asserted-by":"crossref","first-page":"h5079","DOI":"10.1136\/bmj.h5079","article-title":"Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?","volume":"351","author":"Mohan","year":"2015","journal-title":"BMJ"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201611000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T02:05:50Z","timestamp":1718676350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201611000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000324","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}